Zacks small cap research.

Highlights for 2022 and to-date include: TLANDO approved – March 2022. LPCN 1144 end of Phase II meeting with FDA – July 2022. LPCN 2101 IND cleared – July 2022. LPCN 1154 (post-partum depression) pathway to approval clarified – September 2022. Strategic realignment towards CNS disorders – September 2022.

Zacks small cap research. Things To Know About Zacks small cap research.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Jan 5, 2023 · By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a 78.9% increase from the prior year period. Unit volume was 6,050 vehicles in the Zacks Small-Cap Research Spo nsored – Impartial - Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 November 30, 2022 Lisa Thompson 312-265-9154 / [email protected] ... Zacks Inves tment Research Page 3 scr.zacks.com mainly related to capital markets consulting fees incurred as Tenet plans to list its ...Oct 17, 2022 · By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT Uxin Limited (NASDAQ:UXIN) operates a leading e-commerce platform for buying and selling used cars in China. The company also has two physical locations where customers can view and purchase cars in person. The company has recently transitioned to an inventory-owning model which provides customers with a comprehensive transaction

May 15, 2023 · Yes, absolutely. Zacks is worth it. Given that the stocks they rate as a #1 Strong Buy have beat the SP500 by 13.9% on average for the last 34 years, their system works. And the fact that the stocks they rate as a #5 Strong Sell have underperformed the market by 8.4% all but proves their system. Highlights for 2022 and to-date include: TLANDO approved – March 2022. LPCN 1144 end of Phase II meeting with FDA – July 2022. LPCN 2101 IND cleared – July 2022. LPCN 1154 (post-partum depression) pathway to approval clarified – September 2022. Strategic realignment towards CNS disorders – September 2022.Zacks Small-Cap Research M. Marin 312-265 9211 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 August 30, 2022 BTCY: Health Monitoring Ecosystem is Expanding With New & Upcoming Products BCTY is …

© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update First Patient Dosed in Phase 1b/2 Trial for Exebacase in Chronic Knee Prosthetic Joint Infections On April 26, 2023, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 1b/2 clinical trial of exebacase in the setting of a minimally-invasive arthroscopic debridement, antibiotics,

May 4, 2023 · First Quarter 2023 Financial and Operational Results. For the quarter ending March 31, 2023, electroCore Inc. (NASDAQ:ECOR) posted revenues of approximately $2.8 million vs. $1.9 million in the prior year quarter. This represents growth of nearly 50%, driven by increases in the VA/DOD segment and commercial revenues augmented by electroCore’s ... Zacks Small Cap Research. PLX: Back of the Envelope. Read full article. 1. Zacks Small Cap Research. May 30, 2023 at 8:00 AM ...Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0.78 to $16.84 per …Aug 24, 2023 · By Lisa Thompson OTC:NEXCF CSE:TGGL READ THE FULL NEXCF RESEARCH REPORT Nextech (OTC:NEXCF) reported Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. The company had preannounced this number on August 1st. Investors are still awaiting news that Nextech’s 3D modeling services will be available to merchants in Amazon’s Seller Central which is expected to boost

© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Advancing Multiple Clinical Trials in 2023 ESSA Pharma Inc (NASDAQ:EPIX) is developing EPI-7386 as a treatment for prostate cancer. It is a member of a novel class of compounds known as ‘anitens’, which specifically target the androgen …How many stars would you give Zacks Investment Research? Join the 86 people who've already contributed. Your experience matters.By John Vandermosten, CFA. NASDAQ:RVPH. READ THE FULL RVPH RESEARCH REPORT. 2Q:23 Financial and Operational Results. On August 15, 2023, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 2Q:23 financial and operational results and filed its Form 10-Q with the SEC. Since our previous update in …May 4, 2023 · First Quarter 2023 Financial and Operational Results. For the quarter ending March 31, 2023, electroCore Inc. (NASDAQ:ECOR) posted revenues of approximately $2.8 million vs. $1.9 million in the prior year quarter. This represents growth of nearly 50%, driven by increases in the VA/DOD segment and commercial revenues augmented by electroCore’s ... Highlights for 2022 and to-date include: TLANDO approved – March 2022. LPCN 1144 end of Phase II meeting with FDA – July 2022. LPCN 2101 IND cleared – July 2022. LPCN 1154 (post-partum depression) pathway to approval clarified – September 2022. Strategic realignment towards CNS disorders – September 2022.Zacks Investment Research is a Chicago-based research and money management firm founded in 1978 to provide institutional investors with quantitative models ...By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in total suffering from chronic allergic contact dermatitis (ACD) (NCT03680131).

SCR Premium. Receive Initiation Reports PROMPTLY as they are sent out to the marketplace. Access the FULL REPORT CATALOG on any company we cover. Receive the DAILY ALERT EMAIL, containing all of the day's updates, around 5 p.m. EST. Access to REAL-TIME EMAIL ALERTS for any companies covered by Zacks SCR analysts.. …Zacks Small Cap Research. TENX: Prioritizing Levosimendan. Read full article. Zacks Small Cap Research. May 22, 2023 at 6:44 AM ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a …INX (OTC:INXDF) announced that Republic Group, described as “a global financial firm operating a digital merchant bank and a network of investment platforms,” is investing $5.25 million into the company in exchange for approximately 9.5% of outstanding shares. The deal, according to INX, values INX at approximately $50 million before the ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Nov 14, 2023 · A conference call was also held to discuss results with investors. For the third quarter of 2023 ending September 30, 2023 and versus the prior year’s third quarter, no revenues were recognized. Net loss for the third quarter totaled ($73.5) million or ($4.89) per share. Operational expenses rose 67% over 3Q:23 levels as increases related to ... Oct 31, 2023 · Fund Description. The fund was incepted in May 2000 and is managed by Franklin Advisers. The objective of this fund is long-term capital growth. The fund invests at least 80% of its net assets in ...

Investrade has good news to share - we are providing all customers FREE Snapshot research reports from Zacks Investment Research. There are reports on 4400 ...Thomas Kerr, CFA is a Senior Equity Research Analyst with Zacks Small-Cap Research, with over 25 years of securities industry experience in Technology, Consumer, Industrials, Med-Tech, Healthcare & Biotechnology sectors. Prior to joining Zacks in 2021, Tom was Senior Investment Specialist at WestPac Wealth Partners, Chief Investment Officer ... Jan 13, 2023 · By Lisa Thompson OTC:NEXCF READ THE FULL NEXCF RESEARCH REPORT Yesterday Nextech (OTC:NEXCF) preannounced preliminary 2022 revenues of $10.3 million for the year or $1.4 million for Q4 2022. While this looks like a miss compared to our model, it includes $958,822 in revenues eliminated from historical product sales booked in Q1 and Q2 due to reclassifying the pet business as a discontinued In today’s digital age, having a reliable and fast internet connection is essential. When searching for an internet provider, you may come across terms like “unlimited data” and “data caps.” Understanding these terms is crucial to ensure yo...By John Vandermosten, CFA NASDAQ:RVPH RP5063: Retroactive Comparison Against 32 Antipsychotics An estimated 0.25% to 1% of the global population suffers from schizophrenia. To address this estimated 20 million individuals with the chronic disorder there are numerous antipsychotics approved for use. However, a high discontinuation rate due to suboptimal efficacy and serious side effects reveals anOn May 9, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 2022 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. In the last six weeks, Lantern has dosed its first patient in the Phase II Harmonic study, announced receipt of a patent allowance by the USPTO …When it comes to fastening two objects together, cap head bolts and cap head screws are two popular options. They both have a similar appearance, but they differ in their application and usage. In this article, we’ll explore the difference ...Giles Haycock Managing Director (T) 312.265.9351 (M) 312.752.6718 (F) 312.265.9560 (E) [email protected] Twitter: @ZacksSmallCap Steven Ralston, CFA Director of ResearchAug 24, 2023 · By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update HyBryte™ Expanded Treatment Trial Underway On August 10, 2023, Soligenix, Inc. (NASDAQ:SNGX) announced the start of the investigator-initiated study that is designed to examine the expanded treatment, including up to 12 months of treatment, with HyBryte in patients with early-stage cutaneous T cell lymphoma ...

By John Vandermosten, CFA. NASDAQ:RVPH. READ THE FULL RVPH RESEARCH REPORT. 2Q:23 Financial and Operational Results. On August 15, 2023, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 2Q:23 financial and operational results and filed its Form 10-Q with the SEC. Since our previous update in …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

By M. Marin. NASDAQ:NVX. READ THE FULL NVX RESEARCH REPORT. As Novonix (NASDAQ:NVX), an integrated developer and supplier of high-performance materials, equipment and services for the global lithium-ion battery industry, continues to advance its strategy to develop a U.S.-based lithium-ion battery materials supply chain, …On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022.LEER has been making truck accessories since the late 1960s, and LEER fiberglass truck caps dominate the truck cap industry in both Canada and the US, according to Cap World. These fiberglass truck caps are lightweight and known for fitting...By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced 2Q 2023 results. The headline showed that earnings per share of $0.02 were inline with our estimates, driven by the continued impressive improvement in gross margin on sales revenue by another 5% in the quarter …By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ...Knowing which ridge cap you can use for an architectural roof, and which you should not is vitally important to the longevity of the roof. Expert Advice On Improving Your Home Videos Latest View All Guides Latest View All Radio Show Latest ...5 Small Cap Value Stocks to Keep on Your Watch List. 1. Caleres (. CAL Quick Quote. CAL - Free Report) is a specialty retailer with over 1000 retail locations in 68 countries. Its brands include ...Zacks Rank N/A An Investment That’s Easy to Swallow Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 20, 2021 312-265-9588 / [email protected] ZACKS ESTIMATES Revenue Q1 Q2 Q3 Q4 YearIn 4Q22, Novonix Anode Materials was selected to enter negotiations to receive US$150 million in grant funding from the Department of Energy (DOE) to expand its domestic synthetic graphite anode materials production, which we view as a positive. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports …

Zacks Rank N/A BIOR: Precision Release – Surgical Strike on the GI Tract Zacks Small-Cap Research Joh Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. …By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a 78.9% increase from the prior year period. Unit volume was 6,050 vehicles in theZacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 1, 2021 Raising …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Instagram:https://instagram. day trading on thinkorswimdoes fidelity have paper tradingotcmkts curlfnasdaq arm 1. Strong Balance Sheet – MediciNova exited the first quarter of 2023 with approximately $55.3 million in cash and cash equivalents. Due to a low operating cash burn rate, we estimate this is enough to fund operations for at least the next four years. The financial markets continue to be difficult for small-cap biotech companies, and those ...By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent with the filing of Form 20-F. A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update in November include offshore stock trading platformsmdt stock price Zacks Investment Research: A company, founded in 1977, dedicated to providing professional investors with the financial data and analysis needed to make …By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND) best low priced stocks to buy now Jan 5, 2023 · By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND) Novonix Cathode Materials is also expected to play a key role in the growing demand for batteries. Last month NVX launched a new pilot production facility for cathode materials in a new 35,000-square-foot facility. The facility enables Novonix to demonstrate the feasibility of large-scale production.Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Reviva RECOVER Topline Results Data Presentation, October 30, 2023.